CloudHealth Secures Nearly RMB 1 Billion in Strategic Investment to Advance Dual Focus on Scientific Research and Consumer Genomics

According to VCBeat (WeChat ID: vcbeat),Cloud Health Gene and capital institutions such as the Yangzi Technology Venture Capital Equity Investment Fund under Yangzhou State-owned Investment Group, on2016Year10Month31SunReached an equity investment agreement, secured nearly RMB 100 million in strategic investment, with a valuation exceeding10100 millionRMB. In addition, several well-known investment institutions are currently in the process of signing agreements, with completion expected in the near future.Around of financing.

Cloud Health Gene, founded in 2014, is a high-tech genomics company dedicated to the translational applications of precision medicine. As one of the pioneers and advocates of high-throughput sequencing for precision healthcare in China, it was among the first batch of genetic testing demonstration centers designated by the National Development and Reform Commission (NDRC). It also serves as the International Precision Medicine Cooperation Center within the China Pilot Free Trade Zone and has been approved to participate in major national initiatives, including the development of big data standards for precision medicine under the 13th Five-Year Plan.

// Research + Public, Genes + Big Data, Diversified Development //

Cloud Health provides diversified services, covering scientific research, consumer genetic services, and medical big data.

Mass-market genetic services cover popular offerings including personal DNA profiling, tumor genetics, obesity genetics, and personalized medication testing;

Scientific research services include whole-genome, exome, and targeted region sequencing for humans, as well as whole-genome sequencing for animals, plants, and microorganisms. These services are widely applicable to studies such as variant detection, genetic map construction, and population evolution, holding significant scientific and industrial value;

Moreover, Cloud Health boasts a world-class bioinformatics analysis team with robust computational capabilities, offering not only standardized bioinformatics analysis pipelines but also personalized, in-depth data mining services tailored to specific research needs.

Cloud Health has established the world’s most advanced ultra-high-throughput whole-genome sequencing technology platform. Leveraging its integrated ecosystem—comprising medical laboratories, big data centers, innovation hubs, academician and expert workstations, life science centers, and premium clinics—it delivers comprehensive solutions spanning from genetic testing to precision health and precision medicine.

Currently, Cloud Health has established a genetic baseline database for the Chinese population, possessing nearly 20,000 cases of whole-genome data from Chinese individuals, with its sequencing throughput ranking among the top three in China. In the future, Cloud Health will leverage gene technology as its cornerstone to become a globally leading brand in the field of precision health.

// Frequent Moves to Advance Strategic Cooperation //

In addition to its own diversified development, Cloud Health is also actively advancing strategic partnerships:

In June this year, Cloud Health and Predicine, a US-based international precision medicine organization, jointly launched non-invasive cancer tests for lung cancer and prostate cancer. Predicine is dedicated to precision diagnosis, precision treatment, and big data analytics. Its team comprises senior experts and scholars from world-leading enterprises, maintaining an industry-leading position in clinical oncology, liquid biopsy, cancer diagnostics, next-generation sequencing (NGS), biomarker development, drug R&D, clinical drug trials, bioinformatics, and big data cloud computing. This collaboration aims to leverage the complementary strengths of both parties, enabling the rapid clinical application of the latest non-invasive cancer diagnostic technologies.

In the same month, as the 18th Shanghai International Biotechnology and Pharmaceutical Seminar (Bio-Forum) grandly opened, Cloud Health and Quantified Health signed a cooperation agreement. The two parties will jointly develop and promote a series of gut microbiota genetic testing products for precision health management in the future. Through this collaboration, they aim to popularize gut microecological genetic testing in the fields of precision health management and physical examinations, establishing a dynamic human database based on intestinal absorption, metabolism, and antibiotic stress levels, thereby providing strong support for individual health and the optimal functioning of various bodily systems.

In addition to collaborating within the same industry, Cloud Health is also exploring cross-sector partnerships. Cloud Health and Datbao, a commercial insurance platform, have jointly signed a strategic cooperation agreement. In the future, both parties will collaborate on product development and promotion in the fields of consumer health management and precision medicine. The two parties jointly proposed integrating high-throughput gene sequencing tests with follow-up preventive intervention plans into health insurance products to achieve precise health management solutions. In the course of their future cooperation, both parties will jointly establish a comprehensive and meticulous health management procedure, leveraging Datbao’s advantages in health insurance product research, design, and services, to carry out in-depth collaboration based on the model: “Whole Genome Sequencing + Health Insurance = Precision Health Management.”

Cloud Health Gene’s investment by the Yangzi Technology Venture Capital Equity Investment Fund is part of the strategic cooperation between Cloud Health Group and Yangzi State-owned Investment. As the largest state-owned capital investment and operation company in the national-level Nanjing Jiangbei New Area, Yangzi State-owned Investment provides a platform for Cloud Health Group to leverage this partnership to actively participate in the development of the life and health industry, as well as the application of national health and medical big data and the construction of related industrial parks in Nanjing Jiangbei New Area.